Immunocytochemical detection of P-glycoprotein in the management of malignant effusions

J Cancer Res Clin Oncol. 1997;123(8):456-60. doi: 10.1007/BF01372551.

Abstract

P-glycoprotein (P-gp), a cell membrane protein, has been found in multidrug-resistant cancer cells. A total of 104 smears from patients with breast-cancer-associated pleural effusions and ovarian-cancer-related peritoneal effusions were studied for P-gp with the antibody C-219 and the avidin-biotin-immunoperoxidase method. Samples were taken before and 3 and 7 days after intracavitary bleomycin therapy and reaccumulation of effusion was assessed at 30 days. Smears that were P-gp-negative by the 7th day were associated with a good 30-day response to bleomycin in the majority of cases, while P-gp-positive smears were associated with a significant reaccumulation of fluid at 30 days. P-gp status is a valuable prognostic indicator of response to intracavitary bleomycin treatment in effusions from breast or ovarian cancer.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / metabolism
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Ascitic Fluid / drug therapy
  • Ascitic Fluid / metabolism
  • Bleomycin / administration & dosage
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Exudates and Transudates / metabolism*
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Immunohistochemistry
  • Methotrexate / administration & dosage
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism
  • Pleural Effusion / drug therapy
  • Pleural Effusion / metabolism

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Bleomycin
  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate